Intravenous amiodarone in intensive care: Time for a reappraisal?

Intensive Care Medicine

Volumn 26, Issue 12, 2000, Pages 1730-1739

  Hughes, Martin ^a   Binning, Alexander ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Amiodarone; Atrial fibrillation; Atrial tachyarrhythmias; Critical care; Intravenous; Outcome; Perioperative; Ventricular tachyarrhythmias

Indexed keywords

AMIODARONE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; LITHIUM; MEXILETINE; NEUROLEPTIC AGENT; PROCAINAMIDE; PROPAFENONE; QUINIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

BRADYCARDIA; CORONARY CARE UNIT; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; HYPOTENSION; INTENSIVE CARE; LUNG TOXICITY; PATIENT CARE; PERIOPERATIVE PERIOD; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CRITICAL ILLNESS; DRUG INTERACTIONS; DRUG UTILIZATION; ELECTROPHYSIOLOGY; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; LUNG DISEASES; PATIENT SELECTION; TACHYCARDIA, SUPRAVENTRICULAR; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034532804     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340000668     Document Type: Review

References (73)

1. Comparative mechanisms of antiarrhythmic drugs
2. An overview of its pharmacolgical properties and review of its therapeutic use in cardiac arrhythmias
3. Effects of amiodarone on rabbit myocardial beta adrenoceptors and serum thyroid hormones - Absence of a relationship to serum and myocardial drug concentrartions
4. Suppression of time dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone
5. Rate related electrophysiologic effects of long term administration of amiodarone on canine ventricular myocardium in vivo
6. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent
7. Electrophysiologic effects of amiodarone: Experimental and clinical observations relative to serum and tissue concentrations
8. Mechanisms of termination of supraventricular tachycardias by class three antiarrhythmic agents: A comparison of amiodarone and sotalol
9. Mechanisms underlying variability in response to drug therapy: Implications for amiodarone use
10. Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function
11. Comparative haemodynamicc effects of verapamil, flecanide, amiodarone and sotalol in the conscious rabbit
12. Haemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function
13. Haemodynamic responses to amiodarone in critically ill patients receiving catecholamine infusions
14. Comparative haemodynamic effects of amiodarone, sotalol and d-sotalol
15. Effects of amiodarone on cardiac and coronary haemodynamics and on myocardial metabolism in patients with coronary artery disease
16. Haemodynamic effects of short term intravenous amiodarone for hypertrophic cardiomyopathy
17. A randomised haemodynamic comparison of intravenous amiodarone with and without Tween 80
18. Survival trial of antiarrhythmic therapy in congestive heart failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
19. Important differences between short and long term haemodynamic effects of amiodarone in patients with chronic ischaemic heart disease at rest and during ischaemia induced left ventricular dysfunction
20. Divergent effects of chronic amiodarone administration on systolic and diastolic function in patients with heart disease
21. Haemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent tachycardias
22. Haemodynamic effects of intravenous amiodarone
23. Amiodarone: Re-evaluation of an old drug
24. Amiodarone pharmacokinetics
25. Amiodarone and its desethyl metabolite: Tissue distribution and morphologic changes during long term therapy
26. Pharmacology and pharmacokinetics of amiodarone
27. Intravenous amiodarone: Pharmacology, pharmacokinetics and clinical use
28. Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation
29. Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function
30. Pharmacokinetics of amiodarone: Implications for drug therapy
31. Amiodarone digoxin interaction, clinical and experimental observations
32. Amiodarone-digoxin interaction: Clinical significance, time course of development potential pharmacokinetic mechanisms and therapeutic implications
33. Intravenous amiodarone in the treatment of recent onset atrial fibrillation
34. Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation
35. The efficacy and safety of intravenous propafenone vs intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery
36. A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac sugery
37. Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations
38. Intravenous amiodarone in the treatment of various arrhythmias following cardiac operations
39. Electrocardiographic and antiarrhythmic effect of intravenous amiodarone: Results of a prospective, placebo controlled study
40. Amiodarone prophylaxis after coronary artery surgery: A randomised, double blind, placebo controlled trial
41. Prophylactic lidocaine for postoperative coronary artery bypass patients. A double blind, randomised trial
42. The efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhyhthmias
43. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias
44. Efficacy of intravenous amiodarone in the management of paroxysmal atrial fibrillation with fast ventricular response
45. Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients
46. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction
47. Intravenous amiodarone in treatment of recent onset atrial fibrillation: Results of a randomized, controlled study
48. Acute treatment of recent onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone
49. Intravenous flecanide versus amiodarone for recent onset atrial fibrillation
50. A clinical study of intravenous cibenzoline in selected patients with recent onset atrial tachyarrhythmia
51. Intravenous amiodarone versus verapamil for the acute cardioversion of paroxysmal atrial fibrillation to sinus rhythm
52. Intravenous amiodrone for recurrent sustained ventricular tachyarrhythmia
53. Intravenous amiodarone for the rapid treatmerit of life threatening ventricular arrhythmias in critically ill patients with coronary artery disease
54. Intravenous amiodarone in the treatment of refractory life threatening cardiac arrhythmias in the critically ill patient
55. Randomised, double blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, haemodynamically destabilising ventricular tachycardia and fibrillation
56. Significance and management of intractable supraventricular arrhythmias in critically ill patients
57. Cardiac arrhythmias in critically ill patients: Epidemiologic study
58. Management of atrial tachyarrhythmias in the critically ill: A comparison of intravenous procainamide and amidarone
59. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmis: A prospective, randomised trial
60. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias
61. Amiodarone pulmonary toxicity: A multidisciplinary review of current status
62. Anti amiodarone antibodies; detection and relationship to development of side effects
63. Side effects and complications of amiodarone therapy
64. Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: A possible complication of a new antiarrhythmic drug
65. Rapid pulmonary phospholipid accumulation induced by intravenous amiodarone
66. Amiodarone should be used with caution in patients in intensive care
67. Amiodarone and the development of ARDS after lung surgery
68. Acute pulmonary toxicity in an infant from intravenous amiodarone
69. Amiodarone induced torsade de pointes
70. Proarrhythmia with class three antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors and clinical implications
71. Amiodarone associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia
72. Ventricular tachycardias conplicating amiodarone therapy in the presence of hypokalaemia
73. Magnesium: Physiology and pharmacology